Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below are Strong Buys. Each stock received a new Buy rating recently and has a significant upside as well.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
To find more stocks like these, take a look at TipRanks’ Analyst Top Stocks tool. It shows you a real-time list of all stocks that have been recently rated by Top-ranking Analysts.
Here are today’s top stock picks, according to analysts. Click on any ticker to thoroughly research the stock before you decide whether to add it to your portfolio.
Nuvalent (NUVL) – Nuvalent is a clinical-stage biotech company developing therapies for cancers caused by overactive cell growth signals. Today, Piper Sandler analyst Kelsey Goodwin maintained a Buy rating on the stock and increased the price target to $128 from $112 per share. Goodwin said the company is expected to release Phase II ALKOVE-1 trial results soon for its lead drug neladalkib in ALK-positive lung cancer. She believes investors are overlooking the potential impact of this data, which could lift the stock by 18% to 24%, even though some think the results are already priced in. In the last three months, all seven Top Analysts covering the stock have rated it a Buy. Taken together, their 12-month price targets imply an upside of about 33.67%.
Crinetics Pharmaceuticals (CRNX) – Crinetics Pharmaceuticals is a clinical-stage biotech company that develops oral treatments for rare endocrine disorders and endocrine-related tumors. Today, Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on the stock with a price target of $97 per share. Interestingly, 12 of the 13 Top Analysts who recently rated the stock gave it a Buy. Taken together, their 12-month price targets imply an upside of about 99.24%.
Waystar Holding Corp. (WAY) – Waystar Holding is a cloud software company that provides payment, billing and claim-management tools for healthcare providers. Today, Barclays analyst Saket Kalia maintained a Buy rating on the stock with a price target of $50 per share. In the last three months, all five Top Analysts covering the stock have rated it a Buy. Taken together, their 12-month price targets imply an upside of about 28.95%.
Who Are the Top Analysts?
TipRanks ranks financial analysts according to the success rates of their ratings and the average return on each of their ratings. The Top Analysts have each earned a five-star ranking, thanks to the accuracy and profitability of their ratings over time.
See real-time analyst rankings and learn more about the performance of Top Analysts on TipRanks’ Top Wall Street Analysts page.